Xlife Sciences AG Publishes 2023 Annual Report

Xlife Sciences AG / Key word(s): Annual Results
Xlife Sciences AG Publishes 2023 Annual Report

23-Apr-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Zurich, 23rd of April 2024: Xlife Sciences AG (SIX: XLS) reports on the
financial and operational results of 2023 and provides insights into plans
for 2024. Despite global uncertainties, the company remains resilient thanks
to innovative projects and strategic partnerships, managing to complete its
first cash-effective exits.

Operational Progress in 2023

As of December 31, 2023, Xlife Sciences managed 25 project companies, which
have made the following notable progress during the reporting year:

  * Through the acquisition of Synimmune GmbH at the end of December 2023
    via a share deal totaling EUR 32 million, VERAXA Biotech AG successfully
    expanded its internal cancer portfolio to include innovative antibodies
    and antibody-drug conjugates with a clinical asset.

  * FUSE-AI GmbH received EU MDR Class IIa approval for its AI algorithm
    «Prostate.Carcinoma.ai». This development opens up commercial potential
    in 31 countries.

  * Successful exits from other portfolio companies: x-diagnostics GmbH,
    which was acquired by 4D Lifetec AG. This transaction supports the 4D
    Lifetest(TM) in early cancer detection through the AI solution from x
    diagnostics GmbH. Additionally, cash-effective proceeds of CHF 13.6
    million were generated in secondary market transactions.

  * Exclusive collaboration between our portfolio company x-kidney
    diagnostics GmbH and Quant Biomarkers AG, which will advance the asset
    consisting of innovative biomarkers and lead to a licensing agreement.

  * saniva diagnostics GmbH received FDA approval in February 2023 for
    NeuroMex, a screening device for the early detection of diseases such as
    Parkinson's and Alzheimer's.

  * The strengthening and expansion of the patent families of the individual
    project companies are key elements for the value of our portfolio. For
    example, Axenoll Life Sciences AG obtained a strategically significant
    patent from the European Patent Office at the beginning of 2023.

Financial Highlights 2023

  * Xlife Sciences generated revenues of approximately CHF 0.98 million in
    2023 from providing services to project companies (2022: CHF 1.03
    million).

  * The earnings per share (undiluted) were CHF 2.73 (previous year: CHF
    2.72).

  * As of December 31, 2023, the total balance sheet of the company amounted
    to CHF 511.9 million (as of December 31, 2022: CHF 490.2 million).

  * The equity stood at CHF 365.04 million as of December 31, 2023 (as of
    December 31, 2022: CHF 337.7 million).

Outlook for 2024

The start of 2024 is characterized by a focus on international expansion and
strategic partnerships. For instance, FUSE-AI GmbH has already secured
contracts with key resellers such as T-Systems (Switzerland), Mint Medical
(Germany), and Terarecon (USA), paving the way for paying customers from
clinics and practices. Additionally, FDA approval and entry into 13
additional countries are expected in the first half of the year.
Furthermore, FUSE AI GmbH is expanding its portfolio to include additional
indications.

Following the successful launch of a Life Sciences Hub in 2023 in
collaboration with the Department of Health Abu Dhabi, we continued this
ambitious project in 2024 with other significant partners (Thermo Fisher
Scientific and Masdar City). Moreover, Xlife Sciences AG has further
strengthened and expanded its presence in key international markets such as
Asia and the USA.

The team is also set to be enhanced with additional key positions in
Business Development and Partnering. The focus on cash-effective exits
(sales, licensing deals, and possible IPOs), which was established and
implemented for the first time in 2023, will be significantly expanded this
year. This approach will effectively activate key value drivers for our
shareholders and significantly enhance the appeal of our company.

Oliver R. Baumann, CEO of Xlife Sciences AG, emphasizes this outlook with
the words: «The year 2023 was marked by challenging global conditions, but
thanks to our relentless commitment to innovation and quality, we have made
significant progress in the development of our projects. We have achieved
strategic breakthroughs and further solidified our position in the
biotechnology and pharmaceutical industry. Looking ahead to 2024, we are
well-positioned to leverage our technological advances, expand our market
presence, and continue to create sustainable value for our shareholders.»

The complete 2023 annual report, including the consolidated financial
statements of the Xlife Group for 2023, the financial statements of Xlife
Sciences AG for 2023 and the compensation report for 2023 were also
published today, April 23, 2024, at 07:00 AM and are available for download
as PDF documents at https://www.xlifesciences.ch/en/news-and-key-figures
under the «Financial Reports» section.

Financial calendar

     Annual Shareholders Meeting 2024    28 June 2024
     Half-Year Report 2024               19 September 2024

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis
Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG,
Talacker 35,
8001 Zurich,
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange


News Source: Xlife Sciences AG


---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        Xlife Sciences AG
                   Talacker 35
                   8001 Zürich
                   Switzerland
   Phone:          +41 44 385 84 60
   E-mail:         info@xlifesciences.ch
   Internet:       www.xlifesciences.ch
   ISIN:           CH0461929603
   Valor:          A2PK6Z
   Listed:         SIX Swiss Exchange
   EQS News ID:    1886489

End of Announcement EQS News Service
---------------------------------------------------------------------------

1886489 23-Apr-2024 CET/CEST